Paper40487451
Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC.
Littler S and 9 others. iScience, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. Papers, record 40487451. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40487451
- Cell line
- OVCAR-3234 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records10
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Cell lines10
- OVCAR-3The paper gives its RRID234 papers
- Caov-3The paper gives its RRID97 papers
- KuramochiThe paper gives its RRID68 papers
- OVSAHOThe paper gives its RRID43 papers
- RMG-IThe paper gives its RRID43 papers
- COV362The paper gives its RRID40 papers
- OVISEThe paper gives its RRID38 papers
- COV318The paper gives its RRID27 papers
- OVMANAThe paper gives its RRID24 papers
- OV56The paper gives its RRID17 papers
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References92
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16912073 | Validating Aurora B as an anti-cancer drug target. | J Cell Sci | 2006 | https://conductscience.org/library/papers/16912073 | PubMed |
| 2 | 20162290 | Re-evaluating the role of Tao1 in the spindle checkpoint. | Chromosoma | 2010 | https://conductscience.org/library/papers/20162290 | PubMed |
| 3 | 23104886 | STAR: ultrafast universal RNA-seq aligner. | Bioinformatics | 2013 | https://conductscience.org/library/papers/23104886 | PubMed |
| 4 | 20643922 | Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20643922 | PubMed |
| 5 | 2182320 | Negative autoregulation of c-myc transcription. | EMBO J | 1990 | https://conductscience.org/library/papers/2182320 | PubMed |
| 6 | 31068700 | Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | https://conductscience.org/library/papers/31068700 | PubMed |
| 7 | 32071436 | Target gene-independent functions of MYC oncoproteins. | Nat Rev Mol Cell Biol | 2020 | https://conductscience.org/library/papers/32071436 | PubMed |
| 8 | 17157259 | SNIP1 is a candidate modifier of the transcriptional activity of c-Myc on E box-dependent target genes. | Mol Cell | 2006 | https://conductscience.org/library/papers/17157259 | PubMed |
| 9 | 29847804 | Identification of Drivers of Aneuploidy in Breast Tumors. | Cell Rep | 2018 | https://conductscience.org/library/papers/29847804 | PubMed |
| 10 | 31694914 | SUMOylation down-regulates rDNA transcription by repressing expression of upstream-binding factor and proto-oncogene c-Myc. | J Biol Chem | 2019 | https://conductscience.org/library/papers/31694914 | PubMed |
| 11 | 18384750 | Sumoylation of Smad3 stimulates its nuclear export during PIASy-mediated suppression of TGF-beta signaling. | Biochem Biophys Res Commun | 2008 | https://conductscience.org/library/papers/18384750 | PubMed |
| 12 | 34508258 | The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/34508258 | PubMed |
| 13 | 37474739 | The SUMO-NIP45 pathway processes toxic DNA catenanes to prevent mitotic failure. | Nat Struct Mol Biol | 2023 | https://conductscience.org/library/papers/37474739 | PubMed |
| 14 | 12098700 | Sustained loss of a neoplastic phenotype by brief inactivation of MYC. | Science | 2002 | https://conductscience.org/library/papers/12098700 | PubMed |
| 15 | 38321218 | MYC targeting by OMO-103 in solid tumors: a phase 1 trial. | Nat Med | 2024 | https://conductscience.org/library/papers/38321218 | PubMed |
| 16 | 31974379 | Chromosome arm aneuploidies shape tumour evolution and drug response. | Nat Commun | 2020 | https://conductscience.org/library/papers/31974379 | PubMed |
| 17 | 27273739 | Cofactor squelching: Artifact or fact? | Bioessays | 2016 | https://conductscience.org/library/papers/27273739 | PubMed |
| 18 | 35562350 | MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. | Nat Commun | 2022 | https://conductscience.org/library/papers/35562350 | PubMed |
| 19 | 18716624 | Modelling Myc inhibition as a cancer therapy. | Nature | 2008 | https://conductscience.org/library/papers/18716624 | PubMed |
| 20 | 20519624 | Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. | Blood | 2010 | https://conductscience.org/library/papers/20519624 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42819173 | Mechanisms of resistance to PARP inhibitors in advanced epithelial ovarian cancer: biological determinants and therapeutic implications. | Front Oncol | 2026 | https://conductscience.org/library/papers/42819173 | PubMed |
| 42019804 | A Landscape Analysis of Human SUMOylation. | Mol Cell Proteomics | 2026 | https://conductscience.org/library/papers/42019804 | PubMed |
| 41857765 | Transcriptome-driven constraint-based modelling reveals metabolic targets for ovarian cancer. | Cancer Metab | 2026 | https://conductscience.org/library/papers/41857765 | PubMed |
| 40909841 | Integration of cell-type resolved spatial proteomics and transcriptomics reveals novel mechanisms in early ovarian cancer. | medRxiv | 2025 | https://conductscience.org/library/papers/40909841 | PubMed |
| 40466638 | Screening a living biobank identifies cabazitaxel as a strategy to combat acquired taxol resistance in high-grade serous ovarian cancer. | Cell Rep Med | 2025 | https://conductscience.org/library/papers/40466638 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABCB1 | 5243 | PubTator's text mining | https://conductscience.org/library/genes/5243 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
| PML | 5371 | PubTator's text mining | https://conductscience.org/library/genes/5371 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40487451
GET https://conductscience.org/api/papers/v1/40487451/references?page=2